• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, February 9, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Opioid analgesics reduce use of antipsychotics in persons with Alzheimer’s disease

Bioengineer by Bioengineer
March 26, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Initiating an opioid analgesic reduced the use of antipsychotics and benzodiazepines in persons with Alzheimer's disease, a recent study from the University of Eastern Finland shows. These drugs are frequently prescribed to treat behavioural and psychiatric symptoms of dementia, which can be worsened by other symptoms, such as pain. The results were published in International Psychogeriatrics.

The researchers analysed the use of antipsychotics and benzodiazepines six months before and six months after persons with Alzheimer's disease begun using an opioid. These results were then compared to persons with Alzheimer's disease who did not initiate opioid use. After the initiation of an opioid, the researchers found a downward trend in the prevalence of both antipsychotics and benzodiazepines, with the prevalence of antipsychotics reducing more.

The use of antipsychotics and benzodiazepines is very frequent in persons with Alzheimer's disease, but it carries a risk for severe adverse effects, and long-term treatment is generally not recommended. Previous studies have found a decrease in behavioural and psychiatric symptoms of dementia when patients are treated for pain, but this new study now shows, for the first time, a decrease in symptomatic drug use. The study is also the world's first nationwide study on the subject. The results provide further evidence on the importance of proper diagnosis and treatment of pain among persons with dementia.

The study is part of the MEDALZ cohort, which included 3,327 persons with Alzheimer's disease diagnosed during 2010-2011. Each person initiating opioid use was matched with a comparison person with Alzheimer's disease who did not initiate opioid use but was of the same age, gender and region of residence. Data for the study were derived from Finnish nationwide registers.

###

For more information, please contact: Aleksi Hamina, MSc (Pharm), PhD student, School of Pharmacy, University of Eastern Finland, Kuopio, aleksi.hamina(at)uef.fi

Sirpa Hartikainen, professor, School of Pharmacy, University of Eastern Finland Kuopio, sirpa.hartikainen(at)uef.fi

Research article: Impact of opioid initiation on antipsychotic and benzodiazepine and related drug use among persons with Alzheimer's disease. Aleksi Hamina, Piia Lavikainen, Antti Tanskanen, Anna-Maija Tolppanen, Jari Tiihonen, Sirpa Hartikainen, Heidi Taipale. International Psychogeriatrics. Published online 21 March 2018. https://doi.org/10.1017/S1041610217002897

Media Contact

Aleksi Hamina
[email protected]
@UniEastFinland

http://www.uef.fi

http://dx.doi.org/10.1017/S1041610217002897

Share12Tweet7Share2ShareShareShare1

Related Posts

Exercise’s Impact on SASP Biomarkers in Seniors Unexplored

February 9, 2026

UK’s Rising Synthetic Opioid Crisis: Nitazene-Linked Deaths May Be Underreported by Up to 33%

February 9, 2026

Evaluating Digital Diabetes Screening’s B2C Potential in Switzerland

February 8, 2026

Resilient Together: A Promising Post-Diagnosis Intervention

February 8, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Mapping Tertiary Lymphoid Structures for Kidney Cancer Biomarkers

    50 shares
    Share 20 Tweet 13
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Exercise’s Impact on SASP Biomarkers in Seniors Unexplored

UK’s Rising Synthetic Opioid Crisis: Nitazene-Linked Deaths May Be Underreported by Up to 33%

Mapping NYC Foot Traffic: Insights for Urban Planning

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 74 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.